



DOF

Drugs in Oral Fluid

lgcstandards.com/AXIO

ISO/IEC 17043 | ISO/IEC 17025 | ISO 9001



0001

DOF

Drugs in Oral Fluid

The LGC AXIO Drugs in Oral Fluid (DOF) scheme provides performance assessment for laboratories and clinics who provide analytical services for drugs in oral fluid. Samples are provided as real human oral fluid.

Advances in technology have enabled oral fluid testing for the presence of many drugs. Oral fluid collection is often less invasive, relatively easy to perform, and, in forensic situations, can be achieved under close supervision to prevent adulteration or substitution of the samples.

Drug testing is extremely accurate and reliable when all aspects of the testing process are carried out correctly. However, if poor procedures and inadequate testing methods are utilised, the information obtained may be very misleading and inaccurate. To minimise this risk, laboratories should perform routine quality control tests and participate in suitable PT/EQA schemes.

The operation of our DOF scheme is supported by an Advisory Group consisting of members of the professional bodies, scheme participants, and others experienced in the field. The scheme reports on the performance of U.K. participants (who have clinical responsibilities) to the National Quality Assurance Advisory Panels for Chemical Pathology.

DOF

Drugs in Oral Fluid

Test Material*	Analyte*
Urine test materials obtained from volunteers & known drug users which regularly contain mixtures of drugs & their metabolites	Amfetamines and stimulants, Cannabinoids, Cocaine and metabolites, Minor tranquilizers, Non-opiate narcotics, Opiates, Other current drugs and/or metabolites may also be included.

* The full range and availability of test materials and analytes is determined on an annual basis and may be added or removed. For accredited and non-accredited status please see current application form/scheme description.

